11 results on '"Valayer S"'
Search Results
2. Rémission de l’angiœdème par déficit acquis en C1-inhibiteur associé à une hémopathie lymphoïde après splénectomie
- Author
-
Valayer, S., primary, Defendi, F., additional, El Sissy, C., additional, Roos-Weil, D., additional, Ackermann, F., additional, Bouillet, L., additional, Boccon-Gibod, I., additional, Coppo, P., additional, Chafai, N., additional, Kalmi, G., additional, Mcavoy, C., additional, Fain, O., additional, and Gobert, D., additional
- Published
- 2024
- Full Text
- View/download PDF
3. L’acrogeria, une cause exceptionnelle d’acro-ostéolyse
- Author
-
Valayer, S., primary, Hickman, G., additional, Petit, A., additional, Cohen Solal, M., additional, De Sandre Giovannoli, A., additional, and Bourrat, E., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Description des cas possibles de COVID-19 dans un établissement de santé de référence
- Author
-
Souhail, B., primary, Valayer, S., additional, Parisey, M., additional, Le Pluart, D., additional, Ismael, S., additional, Dubert, M., additional, Rioux, C., additional, Descamps, D., additional, Lescure, F.-X., additional, and Yazdanpanah, Y., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Co-infection et surinfection bactérienne chez les patients hospitalisés pour COVID-19: une étude rétrospective monocentrique
- Author
-
Husain, M., primary, Valayer, S., additional, Poey, N., additional, Rondinaud, E., additional, D’Humières, C., additional, Visseaux, B., additional, Deconinck, L., additional, and Lescure, F., additional
- Published
- 2020
- Full Text
- View/download PDF
6. Échec et MAT à la gemcitabine
- Author
-
Valayer, S., primary, Mestiri, R., additional, Cournac, J.M., additional, Doutrelon, C., additional, Lecoules, S., additional, and Aletti, M., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Splenectomy allows remission of angioedema with acquired C1-inhibitor deficiency associated with splenic marginal zone lymphoma.
- Author
-
Valayer S, Defendi F, El Sissy C, Roos-Weil D, Ackermann F, Bouillet L, Boccon-Gibod I, Coppo P, Chafai N, Kalmi G, McAvoy C, Fain O, and Gobert D
- Subjects
- Humans, Female, Remission Induction, Male, Middle Aged, Aged, Angioedema, Splenectomy, Lymphoma, B-Cell, Marginal Zone, Splenic Neoplasms, Complement C1 Inhibitor Protein therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
8. Acrogeria, an exceptional cause of acro-osteolysis.
- Author
-
Valayer S, Hickman G, Petit A, Solal MC, De Sandre Giovannoli A, and Bourrat E
- Subjects
- Humans, Acro-Osteolysis diagnostic imaging, Acro-Osteolysis etiology, Osteolysis etiology
- Abstract
Competing Interests: Conflicts of interest The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
9. Bisphosphonate treatment in inaccessible osteoid osteomas: An alternative therapeutic approach.
- Author
-
Larid G, Valayer S, Jacquier C, Lafforgue P, Laredo JD, and Pham T
- Subjects
- Humans, Male, Adult, Diphosphonates therapeutic use, Zoledronic Acid therapeutic use, Pain, Treatment Outcome, Osteoma, Osteoid diagnostic imaging, Osteoma, Osteoid drug therapy, Osteoma, Osteoid surgery, Bone Neoplasms diagnostic imaging, Bone Neoplasms drug therapy, Bone Neoplasms pathology
- Abstract
Introduction: Osteoid osteoma is a benign osteogenic tumour traditionally treated by surgical excision or percutaneous CT-guided procedures. We describe three cases of osteoid osteomas of which the locations were difficult to access, or for which the procedure was potentially unsafe, involving treatment with zoledronic acid infusions., Case Description: We report here three male 28-to-31-year-old patients with no medical history who had osteoid osteomas located at the second cervical vertebra, the femoral head, and the third lumbar vertebra respectively. These lesions were responsible for inflammatory pain requiring daily treatment with acetylsalicylic acid. Given the impairment risk, all of the lesions were ineligible for surgical or percutaneous treatment. Patients were successfully treated by 3 to 6 monthly zoledronic acid infusions. All patients experienced complete relief of their symptoms allowing aspirin discontinuation, without any side effects. In the first two cases, CT and MRI control showed nidus mineralization and bone marrow oedema regression, correlating with the pain decrease. After 5years of follow-up, there had been no recurrence of the symptoms., Conclusion: In these patients, monthly 4mg zoledronic acid infusions have been safe and effective in the treatment of inaccessible osteoid osteomas., (Copyright © 2023 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. The Potential of Fasting and Caloric Restriction to Mitigate Radiation Damage-A Systematic Review.
- Author
-
Valayer S, Kim D, Fogtman A, Straube U, Winnard A, Caplan N, Green DA, van Leeuwen FHP, and Weber T
- Abstract
Detrimental health effects from ionizing radiation to living organisms is one of the key concerns identified and addressed by Radiation Protection institutions, nationally and internationally on Earth and for human spaceflight. Thus, new methods for mitigating the adverse effects of ionizing radiation are urgently needed for terrestrial health and deep space exploration. Caloric restriction and (intermittent-) fasting have been reported to elicit a variety of immediate and long-term physiological effects. The rapidly growing body of evidence of research studies investigating the effects of caloric restriction and dietary fasting points toward a multitude of benefits affecting numerous physiological systems. Therefore, a systematic review was performed to evaluate the evidence of caloric restriction and dietary fasting on the physiological response to ionizing radiation in humans and animals. All experimental studies of humans, animals, and eukaryotic cell lines available in PubMed, Cochrane library, and specialized databases were searched comparing irradiation post-caloric restriction or fasting to a non-nutritionally restricted control group on a broad range of outcomes from molecular to clinical responses. The initial search yielded 2,653 records. The final analysis included 11 studies. Most studies investigated survival rate or cancer occurrence in animals. Included studies did not reveal any benefit from pre exposure caloric restriction, except when performed with post radiation caloric restriction. However, the effects of pre-exposure fasting suggest increased resilience to ionizing radiation., (Copyright © 2020 Valayer, Kim, Fogtman, Straube, Winnard, Caplan, Green, van Leeuwen and Weber.)
- Published
- 2020
- Full Text
- View/download PDF
11. Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.
- Author
-
Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E, Aboulhab J, Aguirre-MacKenzie M BS, Akoo P MB, ChB, Akpa E MSN, MPH, RN, Akpata R, Albert S BA, MPH, Ale BM MD, MSc, MPH, Alimamy-Bangura S MB, ChB, Andong P MSt, Andrews BC, Anoma S, Atri N MPH, CPH, Augier A MCom, Awuondo K MSc, Ayouba A, Badio M MSc, Bagayoko A, Balde A MPH, Balssa J PharmD, Bangura LM BSc, Barrington K MPA, Barte de Saint Fare E BA, Baseler B MS, Bauder A BA, PMP, Bauduin C MSc, Bawo L MSc, Beavogui AH MD, PhD, Belson M BS, Ben-Farhat S MEng, Bererd M BS, Bernaud N MSc, Beyslow T PharmD, Biai N MSc, Billioux J, Billouin-Frazier S MSc, Binachon B MD, MPH, Blie J MSc, Bockstal V, Boison P MS, Bolay F, Boly A MM, Bonawitz RE MD, MS, Borg AG MCM, Bosompem S PharmD, MSc, Bozman C MSc, Brady T MPH, Browne S RN, BSN, Bullis R, Cagniard B, Cahill K RN, MSc, CCRC, RAC, Cai Y, Camara AA MSc, Camara AK, Camara AM, Campagne A, Campion C MSc, Cantan A BSc, Cash J BS, Chai SP BBio-MedSc, Chambelin F MHist, Chea M BSc, Chêne G MD, PhD, Choi E, Chouinard M MSW, Chung F, Chung L PharmD, Ciancia S MJ, Cisse PN, Cline-Cole E MA, Colin C MSc, Coller BA, Conde DS, Cone K, Cone K MSW, LCSW-C, C-SWHC, Connor L MS, Connor N MSc, Cooper JB MSc, Couffin-Cardiergues S, Coulibaly F BS, Coulibaly M PharmD, MSc, Crew P PharmD, MPH, BCPS, Dabakuyo-Yonli S PharmD, PhD, Dabitao D PharmD, PhD, Damerval T, Davis B MPH, Deen GF MD, MSc, Dekeyster E, Delfraissy JF MD, PhD, Delmas C MSc, Diakite M PharmD, DPhil, Diallo A MD, MPH, Diallo FA, Diallo MS MD, MPH, Diarra A MSc, Diarra S MSc, PhD, Diawara O BS, Dighero-Kemp B BSc, Diop S MSc, PhD, Diouf W, Dixit S, Djenabou B MSc, Doepel L BA, D’Ortenzio E MD, MPH, Doumbia S MD, PhD, Doumbia MM, Douoguih M MD, MPH, Dozier N MSc, Cauwelaert ND, DuChêne A BS, Duvenhage M NDIPIT, Eckes R RN, Elliott E MSc, Enria L, Espérou H, Etienne C MSc, Eyler A HSD, Fakoli L MSc, Fallah M, Fauvel MA MSc, Faye S, Fayiah J MSc, Fleck S, Fofana V BComp, Tchos KF MD, MPH, Franklin K MPhil, MSc, Fusco D, Gaddah A, Gaignet M MSc, Gallagher K, Gardner J BS, Gichini H MSc, Gozalbes JG, Grandits G MS, Gray M BPharm, Greenwood B, Grobler N, Gross R MSc, Grue L RN, BS, BSN, Grund B, Guindo O MSc, PharmD, Gupta S DrPH, MPH, Haidara F, Hamz B PharmD, Hancox E MSc, Hébert JC MSL, Hendriks J, Hensley P MPh, Hensley LE PhD, MSPH, Herpin B MSN, Higgs E MD, DTMH, MIA, Hilton T BPharm, MSc, Hneino M, Höeltermann TA BSc, MPH, Holley HP, Hoover M, Howard N, Hughes M BA, MBA, CPM, PMP, Ilo D MD, MPH, Irvine S BS, Ishola D MD, PhD, Jato Y MPH, Joe M MSc, Johnson M MSc, Kaba AS, Kagan J, Kallon K MSc, Kamara M MBChB, MSc, Kante M BS, Katoudi J MD, MPH, Keita CM, Keita S, Keita S, Kennedy SB MD, MSc, Keshinro B MBBS, FWACP, Kiawu H MSc, Kieh M MD, MSMHC, Killinger B BA, Kinda M MD, MBA, Kirchoff M PharmD, MSc, MBA, Kocher G MSc, Kodio M PharmD, Kohn B BSc, Koivogui L PharmD, PhD, Kojan R, Koli CF é, PharmD, Koli JS é, MD, Kollie D BSc, Kopka S MS, Koroma B BPharm, Kowuor D BSc, MSc, PhD, Kpayieli-Freeman C MSc, Kwast L MSc, Lacabaratz C, Lacarra B, Lambert L BS, Lambeth C BS, Lancrey-javal S PharmD, Lane HC, Langba S BSc, Lawal B MSc, Lee AW, Lee S, Lees S, Lefevre A, Leigh B MD, MSc, Lemarcis F, Lévy Y MD, PhD, Levy-Marchal C, Leyssen M MD, PhD, Lhomme E MD, PhD, Liang J MSc, Linga M MSc, Liu K, Lowe B MPhil, Lysander J MSc, Mahamadou I PharmD, Maljkovic-Berry I, Mambiah M ASc, Manno D MD, PhD, Marchand J MS, Marron L MSc, Massaquoi MB MD, MSc, Masson L MIBL, Matard C BS, Mazur S BS, McCullough J BS, McFadyen K MPH, McLean C, Mercier N PharmD, Michavila P BBus, Miller T RN, BSN, Millimouno NP, Miranda A MS, Mohamed S BJ, Mooney T BA, Muamba D, Mulbah J BPharm, Ndamenyaa RL MD, MSc, Neaton J, Neboua D, Nelson M BSN, MS, Newell K MPH, MEd, Nguyen VK, Njie Y BSc, Njoh W MSN, Novotney-Barry A MSC, Onorato M BS, Onwuchekwa U BSc, Orsega S MSN, FNP-BC, Ortega-Perez I PhD, MPH, Osborne C BS, Otieno T MSC, Oulaï D MS, PMP, Patel S BS, Peart D, Peeters M MSc, Pettitt J MD, PhD, Peiffer-Smadja N MSc, Phillips R, Pierson J, Piot P MD, PhD, Piziali M JD, MSc, Pong S PharmD, Postnikova E, Proffitt C MA, Quach A, Quigley S MSSc, Randunu N BSc, MBA, Richert L MD, PhD, Rivière P MSc, Robinson C, Roy C, Russell AF MS, Sahr P, Saliba K MSc, PhD, Samai M MBBS, PhD, Samake S PharmD, MSc, Sandrus J AA, Sanogo I MsP, MD, Sarro YS PharmD, PhD, Sawadogo S MD, MSc, Sayadi S MD, MPH, Schvartz M, Schwimmer C, Secka F BSc, MSc, MBChB, Sharma H MSc, Shelley D MS, Shobayo B MSc, Siddiqui S MD, MPH, Simon J, Simpson S MS, Sivahera BM, Slater K, Smolskis M BSN, MA, Smout E MD, MSc, Snowden E MA, Soutthiphong AA MSc, Sow A MSc, Sow SO MD, MSc, Sow Y MD, MPH, Stirratt M, Stoop J, Subramaniam G MSc, Surugue L MJ, Swales N MSc, Tamba S RN, BSN, Tang C BSc, Tangara C MSc, Tapia MD, Teahton J MSc, Tegli J MSc, Termote M MSc, Thaurignac G MSC, Thiebaut R MD, PhD, Thompson G BS, Tierney J BSN, MPM, Tindanbil D MSc, Tour A é, PharmD, MPH, PhD, Towalid E BPharm, Traina S BS, Traore A PharmD, Tyee T PharmD, Vallée D PharmD, Vatrinet R, Vincent C MSc, Vogel S RN, BSN, Wallet C MSc, Warren T, Watson-Jones D MD, PhD, Weaver W MSc, Wentworth D MPH, Wesseh C BSc, Whitworth H, Whitworth J, Wiedemann A, Willems W, Wilson B MSc, Wolf J, Wurie A MD, MSc, Yamadjako D MS, Yaradouno M MSc, Yarmie Q MSc, Yazdanpanah Y MD, PhD, Yu S BS, Zeggani Z MSc, and Zhou H BS
- Subjects
- Humans, Adult, Double-Blind Method, Child, Adolescent, Female, Male, Young Adult, Vaccination, Middle Aged, Child, Preschool, Antibody Formation, Ebola Vaccines immunology, Ebola Vaccines administration & dosage, Hemorrhagic Fever, Ebola immunology, Hemorrhagic Fever, Ebola prevention & control, Hemorrhagic Fever, Ebola virology, Antibodies, Viral blood, Antibodies, Viral immunology, Ebolavirus immunology, Ebolavirus genetics, Immunoglobulin G blood, Immunoglobulin G immunology
- Abstract
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP
1,2 ) antibody concentrations after rVSVΔG-ZEBOV-GP or Ad26.ZEBOV, MVA-BN-Filo vaccination with linear mixed-effect regression models. After a post-vaccination peak, each vaccination strategy was associated with a decrease of anti-EBOV GP1,2 antibody concentrations with distinct kinetics, highlighting a less-rapid decline in antibody levels after vaccination by rVSVΔG-ZEBOV-GP. One year after administration of the vaccine, antibody concentrations were higher in children compared to adults for both vaccines, although with different effect sizes: 1.74-fold higher concentrations (95% confidence interval [CI] [1.48; 2.02]) for children 12-17 years old to 3.10-fold higher concentrations (95% CI [2.58; 3.69]) for those 1-4 years old compared to adults for Ad26.ZEBOV, MVA-BN-Filo versus 1.36-fold (95% CI [1.12; 1.61]) to 1.41-fold (95% CI [1.21; 1.62]) higher than these values for adults, with relatively small changes from one age category of children to another, for rVSVΔG-ZEBOV-GP. Antibody concentrations also differed according to geographical location, pre-vaccination antibody concentration, and sex. In combination with knowledge on memory response, characterization of the major determinants of immune response durability of both vaccinations may guide future EVD control protocols. Trial registration: ClinicalTrials.gov identifier: NCT02876328.- Published
- 2025
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.